We are a team of biomedical scientists, and we enjoy identifying experimental therapeutic agents with clinical potential. We believe that our expertise, coupled with our extensive training in critically assessing the quality of the science conducted, can also be spent helping others along the way.
Understanding the science that drives every biotech/pharma company is of great value when conducting investment due diligence.
Analyzing the scientific strengths and limitations requires specific expertise within the field, and because companies understand that investors are more in tune with the company’s business practice and financial health, they tend to oversell their science.
Reading science and clinical journal publications is a great way of understanding the science that drives every pharmaceutical or biotech company. However, peer-reviewed publications are typically written in a very strategic manner. Words and sentence structures are written and organized in such a way to reduce the probability of criticism and ultimately, publication rejection. Non-scientists performing their due diligence typically accept the journal narrative at face value, as opposed to critically analyzing the narrative for what it may be really worth.
We would like to provide a scientific investment thesis, which critically assesses the scientific and clinical aspects that drives a company’s directional purpose, and provide a dissertation that details the qualities that either make for a long-term investment, or not.